NICE has recently approved the use of pembrolizumab  (Keytruda) for adjuvant treatment of melanoma after resection of the primary site and lymph node removal (after removing lymph nodes that can be felt, or after a sentinel node biopsy). The addition of pembrolizumab (which is an immunotherapy) after melanoma surgery is likely to improve the recurrence-free survival in patients.